Copyright Reports & Markets. All rights reserved.

Global Breast Cancer Targeted Drug Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Breast Cancer Targeted Drug by Type
    • 1.3.1 Overview: Global Breast Cancer Targeted Drug Market Size by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Global Breast Cancer Targeted Drug Consumption Value Market Share by Type in 2024
    • 1.3.3 Brand Drugs
    • 1.3.4 Generic Drug
  • 1.4 Global Breast Cancer Targeted Drug Market by Application
    • 1.4.1 Overview: Global Breast Cancer Targeted Drug Market Size by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Hospital
    • 1.4.3 Retail Pharmacy
    • 1.4.4 Other
  • 1.5 Global Breast Cancer Targeted Drug Market Size & Forecast
  • 1.6 Global Breast Cancer Targeted Drug Market Size and Forecast by Region
    • 1.6.1 Global Breast Cancer Targeted Drug Market Size by Region: 2020 VS 2024 VS 2031
    • 1.6.2 Global Breast Cancer Targeted Drug Market Size by Region, (2020-2031)
    • 1.6.3 North America Breast Cancer Targeted Drug Market Size and Prospect (2020-2031)
    • 1.6.4 Europe Breast Cancer Targeted Drug Market Size and Prospect (2020-2031)
    • 1.6.5 Asia-Pacific Breast Cancer Targeted Drug Market Size and Prospect (2020-2031)
    • 1.6.6 South America Breast Cancer Targeted Drug Market Size and Prospect (2020-2031)
    • 1.6.7 Middle East & Africa Breast Cancer Targeted Drug Market Size and Prospect (2020-2031)

2 Company Profiles

  • 2.1 Eli Lilly and Company
    • 2.1.1 Eli Lilly and Company Details
    • 2.1.2 Eli Lilly and Company Major Business
    • 2.1.3 Eli Lilly and Company Breast Cancer Targeted Drug Product and Solutions
    • 2.1.4 Eli Lilly and Company Breast Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 Eli Lilly and Company Recent Developments and Future Plans
  • 2.2 Roche
    • 2.2.1 Roche Details
    • 2.2.2 Roche Major Business
    • 2.2.3 Roche Breast Cancer Targeted Drug Product and Solutions
    • 2.2.4 Roche Breast Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Roche Recent Developments and Future Plans
  • 2.3 Merck & Co.
    • 2.3.1 Merck & Co. Details
    • 2.3.2 Merck & Co. Major Business
    • 2.3.3 Merck & Co. Breast Cancer Targeted Drug Product and Solutions
    • 2.3.4 Merck & Co. Breast Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 Merck & Co. Recent Developments and Future Plans
  • 2.4 Novartis
    • 2.4.1 Novartis Details
    • 2.4.2 Novartis Major Business
    • 2.4.3 Novartis Breast Cancer Targeted Drug Product and Solutions
    • 2.4.4 Novartis Breast Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Novartis Recent Developments and Future Plans
  • 2.5 Pfizer
    • 2.5.1 Pfizer Details
    • 2.5.2 Pfizer Major Business
    • 2.5.3 Pfizer Breast Cancer Targeted Drug Product and Solutions
    • 2.5.4 Pfizer Breast Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Pfizer Recent Developments and Future Plans
  • 2.6 Merck KGaA
    • 2.6.1 Merck KGaA Details
    • 2.6.2 Merck KGaA Major Business
    • 2.6.3 Merck KGaA Breast Cancer Targeted Drug Product and Solutions
    • 2.6.4 Merck KGaA Breast Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 Merck KGaA Recent Developments and Future Plans
  • 2.7 Astellas
    • 2.7.1 Astellas Details
    • 2.7.2 Astellas Major Business
    • 2.7.3 Astellas Breast Cancer Targeted Drug Product and Solutions
    • 2.7.4 Astellas Breast Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 Astellas Recent Developments and Future Plans
  • 2.8 Janssen Biotech
    • 2.8.1 Janssen Biotech Details
    • 2.8.2 Janssen Biotech Major Business
    • 2.8.3 Janssen Biotech Breast Cancer Targeted Drug Product and Solutions
    • 2.8.4 Janssen Biotech Breast Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 Janssen Biotech Recent Developments and Future Plans
  • 2.9 Bristol-Myers Squibb
    • 2.9.1 Bristol-Myers Squibb Details
    • 2.9.2 Bristol-Myers Squibb Major Business
    • 2.9.3 Bristol-Myers Squibb Breast Cancer Targeted Drug Product and Solutions
    • 2.9.4 Bristol-Myers Squibb Breast Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.9.5 Bristol-Myers Squibb Recent Developments and Future Plans
  • 2.10 Gilead Sciences
    • 2.10.1 Gilead Sciences Details
    • 2.10.2 Gilead Sciences Major Business
    • 2.10.3 Gilead Sciences Breast Cancer Targeted Drug Product and Solutions
    • 2.10.4 Gilead Sciences Breast Cancer Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.10.5 Gilead Sciences Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Breast Cancer Targeted Drug Revenue and Share by Players (2020-2025)
  • 3.2 Market Share Analysis (2024)
    • 3.2.1 Market Share of Breast Cancer Targeted Drug by Company Revenue
    • 3.2.2 Top 3 Breast Cancer Targeted Drug Players Market Share in 2024
    • 3.2.3 Top 6 Breast Cancer Targeted Drug Players Market Share in 2024
  • 3.3 Breast Cancer Targeted Drug Market: Overall Company Footprint Analysis
    • 3.3.1 Breast Cancer Targeted Drug Market: Region Footprint
    • 3.3.2 Breast Cancer Targeted Drug Market: Company Product Type Footprint
    • 3.3.3 Breast Cancer Targeted Drug Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Breast Cancer Targeted Drug Consumption Value and Market Share by Type (2020-2025)
  • 4.2 Global Breast Cancer Targeted Drug Market Forecast by Type (2026-2031)

5 Market Size Segment by Application

  • 5.1 Global Breast Cancer Targeted Drug Consumption Value Market Share by Application (2020-2025)
  • 5.2 Global Breast Cancer Targeted Drug Market Forecast by Application (2026-2031)

6 North America

  • 6.1 North America Breast Cancer Targeted Drug Consumption Value by Type (2020-2031)
  • 6.2 North America Breast Cancer Targeted Drug Market Size by Application (2020-2031)
  • 6.3 North America Breast Cancer Targeted Drug Market Size by Country
    • 6.3.1 North America Breast Cancer Targeted Drug Consumption Value by Country (2020-2031)
    • 6.3.2 United States Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 6.3.3 Canada Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 6.3.4 Mexico Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)

7 Europe

  • 7.1 Europe Breast Cancer Targeted Drug Consumption Value by Type (2020-2031)
  • 7.2 Europe Breast Cancer Targeted Drug Consumption Value by Application (2020-2031)
  • 7.3 Europe Breast Cancer Targeted Drug Market Size by Country
    • 7.3.1 Europe Breast Cancer Targeted Drug Consumption Value by Country (2020-2031)
    • 7.3.2 Germany Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 7.3.3 France Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 7.3.4 United Kingdom Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 7.3.5 Russia Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 7.3.6 Italy Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)

8 Asia-Pacific

  • 8.1 Asia-Pacific Breast Cancer Targeted Drug Consumption Value by Type (2020-2031)
  • 8.2 Asia-Pacific Breast Cancer Targeted Drug Consumption Value by Application (2020-2031)
  • 8.3 Asia-Pacific Breast Cancer Targeted Drug Market Size by Region
    • 8.3.1 Asia-Pacific Breast Cancer Targeted Drug Consumption Value by Region (2020-2031)
    • 8.3.2 China Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 8.3.3 Japan Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 8.3.4 South Korea Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 8.3.5 India Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 8.3.6 Southeast Asia Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 8.3.7 Australia Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)

9 South America

  • 9.1 South America Breast Cancer Targeted Drug Consumption Value by Type (2020-2031)
  • 9.2 South America Breast Cancer Targeted Drug Consumption Value by Application (2020-2031)
  • 9.3 South America Breast Cancer Targeted Drug Market Size by Country
    • 9.3.1 South America Breast Cancer Targeted Drug Consumption Value by Country (2020-2031)
    • 9.3.2 Brazil Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 9.3.3 Argentina Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)

10 Middle East & Africa

  • 10.1 Middle East & Africa Breast Cancer Targeted Drug Consumption Value by Type (2020-2031)
  • 10.2 Middle East & Africa Breast Cancer Targeted Drug Consumption Value by Application (2020-2031)
  • 10.3 Middle East & Africa Breast Cancer Targeted Drug Market Size by Country
    • 10.3.1 Middle East & Africa Breast Cancer Targeted Drug Consumption Value by Country (2020-2031)
    • 10.3.2 Turkey Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 10.3.3 Saudi Arabia Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)
    • 10.3.4 UAE Breast Cancer Targeted Drug Market Size and Forecast (2020-2031)

11 Market Dynamics

  • 11.1 Breast Cancer Targeted Drug Market Drivers
  • 11.2 Breast Cancer Targeted Drug Market Restraints
  • 11.3 Breast Cancer Targeted Drug Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Breast Cancer Targeted Drug Industry Chain
  • 12.2 Breast Cancer Targeted Drug Upstream Analysis
  • 12.3 Breast Cancer Targeted Drug Midstream Analysis
  • 12.4 Breast Cancer Targeted Drug Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Breast Cancer Targeted Drug market size was valued at US$ 7355 million in 2024 and is forecast to a readjusted size of USD 14280 million by 2031 with a CAGR of 10.1% during review period.
    Breast cancer is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer. 
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Breast Cancer Targeted Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Breast Cancer Targeted Drug market size and forecasts, in consumption value ($ Million), 2020-2031
    Global Breast Cancer Targeted Drug market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
    Global Breast Cancer Targeted Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
    Global Breast Cancer Targeted Drug market shares of main players, in revenue ($ Million), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Breast Cancer Targeted Drug
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Breast Cancer Targeted Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly and Company, Roche, Merck & Co., Novartis, Pfizer, Merck KGaA, Astellas, Janssen Biotech, Bristol-Myers Squibb, Gilead Sciences, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Breast Cancer Targeted Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Brand Drugs
    Generic Drug
    Market segment by Application
    Hospital
    Retail Pharmacy
    Other
    Market segment by players, this report covers
    Eli Lilly and Company
    Roche
    Merck & Co.
    Novartis
    Pfizer
    Merck KGaA
    Astellas
    Janssen Biotech
    Bristol-Myers Squibb
    Gilead Sciences
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Breast Cancer Targeted Drug product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Breast Cancer Targeted Drug, with revenue, gross margin, and global market share of Breast Cancer Targeted Drug from 2020 to 2025.
    Chapter 3, the Breast Cancer Targeted Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Breast Cancer Targeted Drug market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Breast Cancer Targeted Drug.
    Chapter 13, to describe Breast Cancer Targeted Drug research findings and conclusion.

    Buy now